Status:

TERMINATED

Buspirone as a Potential Treatment for Recurrent Central Apnea

Lead Sponsor:

VA Office of Research and Development

Collaborating Sponsors:

University Hospitals Cleveland Medical Center

Conditions:

Central Apnea

Heart Failure

Eligibility:

All Genders

40-75 years

Phase:

PHASE3

Brief Summary

The purpose of this study is to determine whether buspirone compared to acetazolamide and to placebo will reduce the number and/or severity of breathing pauses during sleep that occur in some patients...

Detailed Description

The hypothesis is that buspirone is a safe, effective drug to reduce the occurrence of recurrent central apnea and irregular breathing found in the setting of heart failure. A secondary hypothesis is ...

Eligibility Criteria

Inclusion

  • Ability to provide informed consent,
  • Ambulatory and in stable condition for the past 4 months,
  • A diagnosis of heart failure with left ventricular systolic dysfunction as evidenced by an ejection fraction \<35%,
  • NYHA class II or III clinical status, and
  • Diagnosis of dilated cardiomyopathy or ischemic cardiomyopathy.

Exclusion

  • Unstable angina, unstable heart failure, acute pulmonary edema, congenital heart disease
  • History of unstable and/or advanced hepatic disease
  • History of renal failure, CrCL \< 30
  • Current use of an SSRI, or use within one month of testing
  • Intrinsic pulmonary diseases: ILD and/or COPD (FEV1/FVC \< 65%)
  • Kyphoscoliosis or neuromuscular disease
  • Suboptimally treated hypothyroidism
  • Use of narcotics or benzodiazepines
  • Use of theophylline or pseudoephedrine
  • Use the following medications:
  • MAO inhibitors
  • diazepam
  • haloperidol
  • nefazodone
  • trazodone
  • erythromycin
  • grapefruit juice
  • itraconazole
  • rifampin
  • ketoconazole
  • ritonavir,
  • cimetidine
  • Known allergy to buspirone or acetazolamide

Key Trial Info

Start Date :

September 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2011

Estimated Enrollment :

8 Patients enrolled

Trial Details

Trial ID

NCT00746954

Start Date

September 1 2008

End Date

December 1 2011

Last Update

March 14 2016

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

VA Medical Center, Cleveland

Cleveland, Ohio, United States, 44106

Buspirone as a Potential Treatment for Recurrent Central Apnea | DecenTrialz